Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE (Preprint)
Gabriele Calaminus(University Hospital Bonn), Claudia E. Kuehni(University of Bern), Harald Binder(Zimmer Biomet (Netherlands)), Claire Berger(Inserm), Eline van Dulmen‐den Broeder(Erasmus MC), Grit Sommer(University of Bern), Aleš Lukš(University Hospital in Motol), Marry M. van den Heuvel‐Eibrink(Princess Máxima Center), Tomáš Kepák(Masaryk University), Martha A. Grootenhuis(University of Amsterdam), Julianne Byrne(Boyne Research Institute), Léonie Casagranda(Centre Hospitalier Universitaire de Saint-Étienne), Claudia Spix(Johannes Gutenberg University Mainz), Katja Baust(University Hospital Bonn), Rahel Kuonen(University of Bern), Kateřina Kepáková(Masaryk University), Jarmila Kruseová(Charles University), Desiree Grabow(Johannes Gutenberg University Mainz), M. van den Berg(Leiden University Medical Center), Peter Kaatsch(Johannes Gutenberg University Mainz), Leontien C M Kremer, Melanie Kaiser(Johannes Gutenberg University Mainz)
Cited by 0
Related Papers
International Classification of Childhood Cancer, third edition
|Cancer|2005|1.5k
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
|Blood|2012|575
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419